৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬



Quantity:
Products
Payment
Delivery
Indications:
Female sterility with hypo- or normogonadotropic ovarian insufficiency: stimulation of follicle growth.
Male sterility with hypo- or normogonadotropic hypogonadism: in combination with HCG to stimulate spermatogenesis.
Pharmacology: Human Menopausal Gonadotrophin (HMG) directly affects ovaries and testes. It has gametotropic and steroidogenic effects.
In ovaries: FSH increases follicle growth and estradiol production by aromatizing androgens under LH influence.
In testes: FSH transforms premature Sertoli cells to mature ones, aiding sperm development. High androgen concentration is required, achieved by prior HCG treatment. HMG is not effective orally; administered intramuscularly (i.m.) or subcutaneously (s.c.). Peak serum FSH occurs 6–48 hours (i.m.) and 6–36 hours (s.c.), with half-life ~51–56 hours. Excreted renally.
Dosage:
Females: 75–150 IU FSH daily i.m./s.c., adjusted by ovarian response (ultrasound, estradiol). Ovulation induced with 5000–10000 IU HCG 1–2 days after last HMG dose.
Males: Initially 2 × 5000 IU HCG weekly until testosterone normalizes, then add HMG (3 × 75–150 IU FSH + 75–150 IU LH weekly).
Administration: Intramuscular or subcutaneous injection.
Patient Selection:
Females: Full gynecological/endocrinological evaluation, rule out pregnancy, primary ovarian failure, uterine/tubal pathology, endometrial abnormalities.
Males: Documented lack of pituitary function, low testosterone, low gonadotropins. Rule out primary testicular failure.
Interactions: Unknown; can be injected with HCG in male infertility.
Contraindications:
Females: Pregnancy, ovarian enlargement/cysts (non-PCOS), unexplained bleeding, uterine/ovarian/breast tumors, hypersensitivity, high FSH (primary ovarian failure), uncontrolled thyroid/adrenal dysfunction, infertility causes other than anovulation.
Males: Prostate carcinoma, testicular tumors, normal gonadotropin levels, primary testicular failure, infertility other than hypogonadotropic hypogonadism.
Pregnancy & Lactation: Not indicated during pregnancy or lactation.
Precautions & Warnings: Risk of miscarriage, multiple or ectopic pregnancies. Monitor ovarian activity closely (ultrasound, estradiol). Stop treatment if hyperstimulation occurs. Severe ovarian hyperstimulation syndrome may be life-threatening.
Overdose Effects: Can cause ovarian hyperstimulation. Severity ranges from mild enlargement to life-threatening cysts, ascites, hydrothorax, thromboembolic events. Requires close monitoring, hospitalization if severe.
Undesirable Effects: Febrile reactions, flu-like symptoms, GI upset, injection site reactions, rash, dizziness, tachycardia, dyspnea. Reported pregnancy outcomes: ectopic pregnancy, congenital abnormalities.
Therapeutic Class: Female sex hormones
Storage Conditions: Store at 2–8°C. Do not freeze. Below 25°C for max 3 months. Protect from light, keep dry. Use reconstituted solution immediately; discard remainder.






Female infertility, Male infertility, In vitro fertilisation procedures or other assisted conception techniques
$4e
Ovarian cysts or enlargement not caused by polycystic ovarian syndrome; tumors of breast, uterus, ovaries, testes or prostate; vaginal bleeding of unknown cause; pregnancy and lactation.
Human menopausal gonadotrophins possess both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activities.
Hyperprolactinemia or tumors of the pituitary or hypothalamus. Ovarian enlargement at risk of rupture, care in pelvic examinations. Risk of multiple births.
Ovarian hyperstimulation, risk of multiple pregnancy and miscarriage, hypersensitivity and local reactions at Inj site, nausea, vomiting, joint pain, fever. In men, gynecomastia, acne, weight gain.\r\nPotentially Fatal: Rupture of ovarian cysts and intraperitoneal haemorrhage.
Drugs with luteinising hormone activity may increase risk of ovarian hyperstimulation syndrome.
N/A
